专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US11111496B2 Methods and microorganisms for making 2,3-butanediol and derivatives thereof from C1 carbons 有权
公开(公告)号：US11111496B2
公开(公告)日：2021-09-07
申请号：US16481799
申请日：2018-01-30
申请人： INTREXON CORPORATION
发明人： Xinhua Zhao , Mark Anton Held , Tina Huynh , Lily Yuin Chao , Na Trinh , Matthias Helmut Schmalisch , Bryan Yeh , James Kealey , Kevin Lee Dietzel
IPC分类号： C12N15/52 , C12N1/20 , C12N9/00 , C12N9/88 , C12N15/74 , C12P5/02 , C12P7/16 , C12P7/18 , C12N9/04 , C12N9/10
摘要： Genetically modified microorganisms that have the ability to convert carbon substrates into chemical products such as 2,3-BDO are disclosed. For example, genetically modified methanotrophs that are capable of generating 2,3-BDO at high titers from a methane source are disclosed. Methods of making these genetically modified microorganisms and methods of using them are also disclosed.

2. 发明授权

US10851119B2 Boron-containing diacylhydrazines 有权
公开(公告)号：US10851119B2
公开(公告)日：2020-12-01
申请号：US16580343
申请日：2019-09-24
申请人： Intrexon Corporation
发明人： Sheela K. Chellappan , Robert E. Hormann , Inna Shulman
IPC分类号： C07F5/02 , C07F5/04 , C07F7/08
摘要： The present disclosure provides boron-containing diacylhydrazines having Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, R4, and R5 are defined as set forth in the specification. The present disclosure also provides the use of boron-containing diacylhydrazines is ecdysone receptor-based inducible gene expression systems. Thus, the present disclosure is useful for applications such as gene therapy, treatment of disease, large scale production of proteins and antibodies, cell-based screening assays, functional genomics, proteomics, metabolomics, and regulation of traits in transgenic organisms, where control of gene expression levels is desirable.

3. 发明授权

US10648003B2 Site-specific serine recombinases and methods of their use 有权
公开(公告)号：US10648003B2
公开(公告)日：2020-05-12
申请号：US16003266
申请日：2018-06-08
申请人： Intrexon Corporation
发明人： Malla Padidam
IPC分类号： C12N15/90 , C12N9/00 , C12N9/22 , C12N15/52 , C12N15/79
摘要： The present invention provides a method for obtaining site-specific recombination in a eukaryotic cell, the method comprising providing a eukaryotic cell that comprises a first recombination attachment site and a second recombination attachment site; contacting the first and second recombination attachment sites with a prokaryotic recombinase polypeptide, resulting in recombination between the recombination attachment sites, wherein the recombinase polypeptide can mediate recombination between the first and second recombination attachment sites, the first recombination attachment site is a phage genomic recombination attachment site (attP) or a bacterial genomic recombination attachment site (attB), the second recombination site is attB or attP, and the recombinase is selected from the group consisting of a Listeria monocytogenes phage recombinase, a Streptococcus pyogenes phage recombinase, a Bacillus subtilis phage recombinase, a Mycobacterium tuberculosis phage recombinase and a Mycobacterium smegmatis phage recombinase, provided that when the first recombination attachment site is attB, the second recombination attachment site is attP and when the first recombination attachment site is attP, the second recombination attachment site is attB. The invention also describes compositions, vectors, and methods of use thereof, for the generation of transgenic cells, tissues, plants, and animals. The compositions, vectors and methods of the present invention are also useful in gene therapy applications.

4. 发明授权

US10584351B2 Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof 有权
公开(公告)号：US10584351B2
公开(公告)日：2020-03-10
申请号：US15648623
申请日：2017-07-13
申请人： Intrexon Corporation
发明人： Jeremiah F. Roeth , Charles C. Reed , Brandon Cuthbertson , Sunil Chada , William E. Fogler
IPC分类号： C12N15/861 , C07K14/55 , A61K38/20 , C07K14/47 , C12N15/85 , C12N15/86 , C07K14/54 , A61K38/19 , A61K38/21 , A61K38/44 , A61K48/00 , C12N5/0784
摘要： This invention relates to the field of therapeutics. Most specifically, the invention provides methods of generating conditionally expressing vectors for one or more immuunomodulators under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals. These vector may be provided to treat a variety of disorders, e.g., neoplastic disorders, through direct injection or through in vitro engineered cells, such as dendritic cells.

5. 发明申请

US20190233834A1 CONTROL OF PHENOTYPE IN PLANTS 审中-公开
公开(公告)号：US20190233834A1
公开(公告)日：2019-08-01
申请号：US16316783
申请日：2017-07-25
申请人： INTREXON CORPORATION
发明人： Sekhar BODDUPALLI , Andrey BOUKHAROV , Rio STAMLER , Zhongsen LI , Arianne TREMBLAY , Stephen SCHAUER , Shiv B. TIWARI , John SALMERON
IPC分类号： C12N15/82
CPC分类号： C12N15/8217 , C12N15/8218 , C12N15/825 , C12N15/827 , C12N15/8273 , C12N15/8274 , C12N15/8281 , C12N15/8282 , C12N15/8283 , C12N15/8286
摘要： The invention provides a compositions and methods for controlling phenotypic traits in plants. Genes of interest are placed under the control of a gene switch to allow inducible control or expression of a gene of interest “on-demand” by treatment of the plant with a chemical ligand.

6. 发明申请

US20190062394A1 Improved Therapeutic Control of Proteolytically Sensitive, Destabilized Forms of Interleukin-12 审中-公开
公开(公告)号：US20190062394A1
公开(公告)日：2019-02-28
申请号：US15767298
申请日：2016-10-10
申请人： Intrexon Corporation
发明人： Ramya YARLAGADDA , Charles REED , Charles Andrew (Marshall) STEWART , Peter EMTAGE , Rutul SHAH , Timothy CHAN
IPC分类号： C07K14/54 , A61P35/00
摘要： The present invention relates to modified forms of IL-12. These modified forms of IL-12 may be engineered to have a shortened in vivo half-life compared and/or enhanced localization of biological effects compared to that of corresponding non-modified form of IL-12. Short half-life and membrane bound forms of IL-12 may provide greater therapeutic control for in vivo therapeutic delivery, in particular when used in combination with ligand inducible delivery of IL-12. Modified forms of IL-12 engineered to have shortened in vivo half-life and/or enhanced localization of biological effects include heterodimeric p35/p40, single chain and membrane bound forms of IL-12 wherein a naturally occurring IL-12 amino acid sequence is genetically modified to destabilize IL-12 tertiary structure/polypeptide folding and enhance susceptibility of the IL-12 molecule to in vivo proteolytic degradation.

7. 发明授权

US10087231B2 Substitution mutant receptors and their use in an ecdysone receptor-based inducible gene expression system 有权
公开(公告)号：US10087231B2
公开(公告)日：2018-10-02
申请号：US14972901
申请日：2015-12-17
申请人： Intrexon Corporation
发明人： Subba Reddy Palli , Marianna Zinovievna Kapitskaya
IPC分类号： G01N33/53 , C07K14/705 , C07K14/72 , C12N15/63
摘要： This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to novel nuclear receptors comprising a substitution mutation and their use in a nuclear receptor-based inducible gene expression system and methods of modulating the expression of a gene within a host cell using this inducible gene expression system.

8. 发明授权

US10081817B2 Site-specific serine recombinases and methods of their use 有权
公开(公告)号：US10081817B2
公开(公告)日：2018-09-25
申请号：US15338961
申请日：2016-10-31
申请人： Intrexon Corporation
发明人： Malla Padidam
IPC分类号： C12N15/90 , C12N9/00 , C12N9/22 , C12N15/52 , C12N15/79
CPC分类号： C12N15/907 , C12N9/00 , C12N9/22 , C12N15/52 , C12N15/79 , C12Y301/22
摘要： The present invention provides a method for obtaining site-specific recombination in a eukaryotic cell, the method comprising providing a eukaryotic cell that comprises a first recombination attachment site and a second recombination attachment site; contacting the first and second recombination attachment sites with a prokaryotic recombinase polypeptide, resulting in recombination between the recombination attachment sites, wherein the recombinase polypeptide can mediate recombination between the first and second recombination attachment sites, the first recombination attachment site is a phage genomic recombination attachment site (attP) or a bacterial genomic recombination attachment site (attB), the second recombination site is attB or attP, and the recombinase is selected from the group consisting of a Listeria monocytogenes phage recombinase, a Streptococcus pyogenes phage recombinase, a Bacillus subtilis phage recombinase, a Mycobacterium tuberculosis phage recombinase and a Mycobacterium smegmatis phage recombinase, provided that when the first recombination attachment site is attB, the second recombination attachment site is attP and when the first recombination attachment site is attP, the second recombination attachment site is attB. The invention also describes compositions, vectors, and methods of use thereof, for the generation of transgenic cells, tissues, plants, and animals. The compositions, vectors and methods of the present invention are also useful in gene therapy applications.

9. 发明申请

US20180126007A1 Therapeutic Gene-Switch Constructs and Bioreactors for the Expression of Biotherapeutic Molecules, and Uses Thereof 审中-公开
公开(公告)号：US20180126007A1
公开(公告)日：2018-05-10
申请号：US15637624
申请日：2017-06-29
申请人： Intrexon Corporation
发明人： Bethany Lynn MERENICK , Robert P. Beech , Thomas D. Reed , Anna P. Tretiakova , Richard E. Peterson
IPC分类号： A61K48/00 , A61K31/7088 , C12N15/63 , C12N15/85
CPC分类号： A61K48/0066 , A61K31/7088 , A61K35/12 , C12N15/635 , C12N15/85 , C12N2510/02 , C12N2830/002 , C12N2830/15
摘要： The present invention relates to methods and compositions for treating, ameliorating or preventing a disease or disorder in a subject by introducing into cells of the subject a therapeutic gene switch construct that controls expression of one or more therapeutic products.

10. 发明申请

US20170312315A1 Engineered Dendritic Cells and Uses for the Treatment of Cancer 审中-公开
公开(公告)号：US20170312315A1
公开(公告)日：2017-11-02
申请号：US15591468
申请日：2017-05-10
申请人： Intrexon Corporation , University of Pittsburgh-Of The Commonwealth System Of Higher Education
发明人： Mark BRAUGHLER , Prasanna Kumar , Walter J. Storkus , Hideho Okada
IPC分类号： A61K35/15 , A61K31/4245 , G01N33/68 , C07K14/54 , A61K31/00 , C12N5/0784 , A61K31/166 , A61K45/06 , A61K38/00
CPC分类号： A61K35/15 , A61K31/00 , A61K31/166 , A61K31/4245 , A61K38/00 , A61K45/06 , C07K14/5434 , C07K2319/715 , C12N5/0639 , C12N2501/23 , C12N2501/24 , C12N2510/00 , C12N2710/10343 , C12N2830/002 , C12N2840/203 , G01N33/6866 , G01N2333/57 , G01N2800/52 , A61K2300/00
摘要： This invention provides the field of therapeutics. Most specifically present invention provides methods of generating in vitro engineered dendritic cells conditionally expressing interleukin-12 (IL-12) under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals including human.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式